Abstract:Background: Under aerobic growth conditions, mitochondria are the major producers of cellular ATP and crucial for the proper performance of organs and tissues. This applies especially to cells with high energy demand, such as the renal proximal tubule epithelium. Mitochondrial dysfunction contributes to the pathology of human health conditions, including various kidney diseases. The improvement of mitochondrial function ameliorates some of these pathologies. This can potentially be achieved with pharmacological compounds. For example, long-term treatment with activators of 5'-AMP activated kinase (AMPK) enhances mitochondrial biogenesis. However, pharmacological damage control during acute cell injury requires that the short-term effects of these compounds and the impact on healthy cells are also understood. It was our objective to define the changes elicited by established modulators of AMPK activity in healthy renal proximal tubule cells. Methods: Our work combines confocal microscopy with quantitative image analysis, 3D image reconstruction and Western blotting to provide novel insights into the biology of mitochondria. Specifically, we evaluated the effects of pharmacological AMPK modulators (compound C, AICAR, phenformin, resveratrol) on mitochondrial polarization, morphology and heterogeneity. Microscopic studies generated information at the single cell and subcellular levels. Our research focused on LLC-PK1 cells that are derived from the renal proximal tubule. Mitochondrial heterogeneity was also examined in MCF7 breast cancer cells. Results: Pharmacological agents that affect AMPK activity in renal proximal tubule cells can alter mitochondrial organization and the electrochemical potential across the inner mitochondrial membrane. These changes were compound-specific. Short-term incubation with the AMPK inhibitor compound C caused mitochondrial hyperpolarization. This was accompanied by mitochondrial fragmentation. By contrast, AMPK activators AICAR, phenformin and resveratrol had little impact. We further show that the biological properties of mitochondria are determined by their subcellular location. Mitochondria at the cell periphery displayed higher MitoTracker/Tom70 values as compared to organelles located in the vicinity of the nucleus. This was not limited to renal proximal tubule cells, but also observed in MCF7 cells. Pharmacological AMPK modulators altered these location-dependent properties in a compound-specific fashion. While the region-dependent differences were enhanced with phenformin, they were ameliorated by resveratrol. Discussion: We evaluated the rapid changes in mitochondrial characteristics that are induced by pharmacological AMPK modulators. Our research supports the concept that pharmacological agents that target AMPK can rearrange mitochondrial networks at the single cell level. Collectively, these insights are relevant to the development of proper strategies for the short-term adjustment of mitochondrial performance.

Abstract 17221: AMPK Regulation of Microtubule Dynamics in Cardiac Hypertrophy

AMPK Attenuates Microtubule Proliferation in Cardiac Hypertrophy.

Activation of AMPK Inhibits Cardiomyocyte Hypertrophy by Modulating of the FOXO1/MuRF1 Signaling Pathway in Vitro

GW24-e2121 Adenosine Monophosphate-Activated Protein Kinase Attenuates Cardiomyocyte Hypertrophy Through Regulation of FOXO3a/MAFbx Signalling Pathway

Alpha1 catalytic subunit of AMPK modulates contractile function of cardiomyocytes through phosphorylation of troponin I

Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes.

AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

Adenosine Kinase Attenuates Cardiomyocyte Microtubule Stabilization and Protects Against Pressure Overload-Induced Hypertrophy and LV Dysfunction.

Abstract 21116: Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

Adenosine Regulation of Microtubule Dynamics in Cardiac Hypertrophy.

Amp Activated Protein Kinase-Alpha 2 Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice

AMPK and Cardiac Remodelling

AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions

Abstract 15090: AMP-Activated Protein Kinase Upregulates Sodium-Dependent Glucose Transporter SGLT1, Which Contributes to Cardiac Ischemia-Reperfusion Injury

The role of AMP-activated protein kinase in the cardiovascular system

Abstract 73: Aberrant Activation of γ2-AMPK Increases Cardiac Growth Through Cellular Hypertrophy and Hyperplasia

Regulation of miR-199a expression by AMPK in cardiac tissues

Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction

Defining the short-term effects of pharmacological 5'-AMP activated kinase modulators on mitochondrial polarization, morphology and heterogeneity